The present invention provides a method for activating AMP-dependent protein kinase (AMPK) using an aporphine alkaloid derivative.
Aporphine alkaloid is a compound with tetracyclic structure, and has different substituents on the aromatic rings. The aporphine alkaloid with many biological activities which can be isolated from the plants such as Lauraceae, Papaveraceae, Menispermaceae and Fumariaceae, and the pharmacological activity of aporphine alkaloid includes anti-arrhythmic, anti-platelet aggregation, vasodilation, α1-adrenoceptor antagonists or ischemic diseases.
AMP-dependent protein kinase (AMPK) is a type of protein kinase that maintains the regulation of energy metabolism in cells, characterized in that it can bind with AMP and maintain the balance between the generation and consumption of ATP through AMP, and thus maintain the balance of energy metabolism. Meanwhile, AMPK can also modulate cell growth and proliferation, establish and stabilize cell polarity, regulate animal lifespan, and modulate physiological rhythms. In recent years, targeting AMPK activation has become one of the key points in pharmaceutical development. Therefore, the pharmaceutical industry is actively pursuing the development of new AMPK activators.
It is unexpectedly found in the prevent invention that certain aporphine alkaloid derivative, such as 1,10-dihydroxyaporphine hydrobromide, is effective in the activation of AMPK.
In one aspect, the present invention provides a method for activating the AMP-dependent protein kinase (AMPK) in a subject comprising administering the subject with a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the general Formula I or a pharmaceutically acceptable salt:
wherein R is H, alkyl or allyl; R1 is H or acyl (RaCH2CO); R2 and R3 are each independently H, OH, alkyl, halide or alkoxy (RaCH2—O—) group; wherein Ra is H or alkyl group.
In one example of the present invention, said compound having Formula I is 1,10-dihydroxyaporphine or pharmaceutically acceptable salt thereof.
In another example of the present invention, said compound having Formula I is 1,10-dihydroxyaporphine hydrobromide.
In still another aspect, the present invention provides a method for treating the AMPK-related disease in a subject comprising administering the subject with a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the general Formula I or a pharmaceutically acceptable salt of the present invention, wherein the treatment is achieved through the activation of AMPK by the compound having the general Formula I or a pharmaceutically acceptable salt; wherein said AMPK-related disease is cancer. The compound having Formula I or a pharmaceutically acceptable salt of the present invention also has an effect in anti-inflammation or promoting wound healing.
Those and other aspects of the present invention may be further clarified by the following descriptions and drawings of preferred embodiments. Although there may be changes or modifications therein, they would not betray the spirit and scope of the novel ideas disclosed in the present invention.
The drawings presenting the preferred embodiments of the present invention are aimed at explaining the present invention. It should be understood that the present invention is not limited to the preferred embodiments shown. The data in the figures and examples are shown as mean±standard deviation (SD), determined by the paired t-test. Significant differences are shown as follows: *: P<0.005; **: P<0.001; #: P=0.067.
Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which this invention belongs.
Unless clearly specified herein, meanings of the articles “a,” “an,” and “said” all include the plural form of “more than one.” Therefore, for example, when the term “a component” is used, it includes multiple said components and equivalents known to those of common knowledge in said field.
As used herein, the term “activating” or “activation” refers to an action to make a molecule active, or to cause a molecule to function or act. In the invention, the activation means that the compound cause AMPK to function in the subject.
As used herein, the term “substituted” or “substitution” refers to where a functional group in a chemical compound is replaced by another group.
As used herein. the term “subject” refers to a human or a mammal, such as a patient, a companion animal (e.g., dog, cat, and the like), a farm animal (e.g., cow, sheep, pig, horse, and the like) or a laboratory animal (e.g., rat, mouse, rabbit, and the like).
The term “AMPK” as used herein is the abbreviation of AMP-dependent protein kinase, which refers to a type of protein kinase that regulates energy metabolism in cells, being the major regulatory factor in many biological processes. The signaling pathway of AMPK includes metabolism of glucose and lipids, and influences the expression of relevant genes and proteins. When AMPK is phosphorylated, its activity will increase and downstream proteins in the AMPK signaling pathway will be further regulated, and thereby metabolism in the liver, skeletal muscles, heart, lipid tissues and pancreas will be regulated. Therefore, medications effective in AMPK activation can be potentially effective in treating many diseases, such as metabolism diseases (such as diabetes), cancer, and cardiovascular diseases (such as atherosclerosis and ischemic heart disease). They can also be used for anti-inflammation or promoting wound healing. The mode of action of AMPK activators including anti-inflammatory activities in vascular endothelial cells has been established in some preclinical and clinical findings; therefore, AMPK is also considered as a drug target in treating cardio-metabolic disease.
The term “alkyl group” used herein refers to linear or branched monovalent hydrocarbons containing 1-20 carbon atoms, such as alkyl groups with 1-10 carbons, preferably alkyl groups with 1-6 carbons, more preferably alkyl groups with 1-3 carbons. Examples of alkyl groups include, but not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and t-butyl.
The term “halide” used herein refers to is a binary compound, of which one part is a halogen atom and the other part is an element or radical that is less electronegative (or more electropositive) than the halogen. Examples of halide include, but not limited to fluoride, chloride, bromide, or iodide.
As evidenced in the examples, 1,10-dihydroxyaporphine hydrobromide has an excellent effect in AMPK activation. Accordingly, the present invention provides a method for activating the AMP-dependent protein kinase (AMPK).
According to the invention, the active compound has the general Formula I:
where R is H, alkyl or allyl; R1 is H or acyl (RaCH2CO); R2 and R3 are each independently H, OH, alkyl, halide or alkoxy (RaCH2—O—) group; wherein Ra is H or alkyl group.
An embodiment of the active compound of the present invention is the compound having the general Formula I, wherein R=Me (methyl), and R1═R2═R3═H, which compound is 1,10-dihydroxyaporphine having the following formula:
Another embodiment of the active compound of the present invention is 1,10-dihydroxyaporphine hydrobromide.
As shown in the examples of the present invention, the compound having Formula I of the present invention, such as 1,10-dihydroxyaporphine hydrobromide, has an effect of activating AMPK.
In addition, the compounds having Formula I of the present invention are effective in AMPK activation so as to achieve the effect of treatment, and thus are useful in treating AMPK-related diseases. For examples, AMPK-related disease is selected from the group consisting of cancer, cardiovascular diseases, and metabolism diseases. In addition, it is also considered to have an effect in anti-inflammation or promoting wound healing.
According to the present invention, said compound having Formula I can be formulated into any forms of medications that are well known or commonly used in the pharmaceutical field, and can be prepared into a composition, according to any techniques well known in the pharmaceutical field, comprising a therapeutically effective amount of said compound in combination with a commonly used carrier or a pharmaceutically acceptable carrier.
The term “carrier” or “pharmaceutically acceptable carrier” used herein includes, but not limited to, pharmaceutically acceptable excipients, fillers, diluents, or the like, including those well known to one of ordinary skills in the pharmaceutical field.
The present invention is explained in the above description of the invention and the following examples, which should not be used to restrict the scope of the present invention.
Acetonitrile (MeCN or ACN) (250 mL), boldine-hydrochloride (5.2 g), 5-chloro-1-phenyl-1-H tetrazol (TzCl) (6.5 g), potassium carbonate (K2CO3) (10.0 g) and potassium iodide (KI) (129.2 mg) were added sequentially into a 500 mL round-bottom flask and the mixture under nitrogen was refluxed at 90° C. for 24 hours. The concentrate obtained by concentration of the reaction mixture under reduced-pressure was recrystallized from water/MeCN to give 2,9-O,O-diphenyltetrazolyl-boldine (7.0 g, 80%).
Acetic acid (HOAc) (80 mL), 10% palladium on carbon (Pd/C) (2.0 g), magnesium powder (675.5 mg) and 2,9-O,O-diphenyltetrazolyl-boldine (6.8 g) were added sequentially into a hydrogenation flask. After degassing and H2-filling procedures, the reaction mixture was stirred under 200 psi H2 at 50-60° C. for 3 days. The resultant suspension was diluted with 50 mL methanol, and filtered through a Celite cake. The residues on Celite were washed with methanol. The residue obtained from concentration of the filtrate and washing solution under reduced-pressure was dissolved in 50 mL water, and adjusted the pH to 8.0 by 25% ammonia water, and partitioned with chloroform (80 mL×3). The combined chloroform layers were dehydrated over anhydrous sodium sulfate and were concentrated to give 1,10-dimethoxyaporphine (2.8 g, 87%).
The mixture of 48% hydrobromide (HBr) (10 mL) and 1,10-dimethoxyaporphine (1.0 g) in a 50 mL round-bottom flask was refluxed under nitrogen at 110° C. for 2 hours. After cooling, the resultant precipitate was filtered and washed with acetone to give 1,10-dihydroxyaporphine hydrobromide (833.1 mg, 71%). The 1,10-dihydroxyaporphine can be obtained by neutralization process of 1,10-dihydroxyaporphine hydrobromide. The above synthetic steps were shown in
Based on the spectroscopic analysis, the 1H and 13C NMR spectroscopic data and ESIMS data of 2,9-O,O-diphenyltetrazolyl-boldine are as follows:
1H H NMR (CDCl3, 400 MHz) δ 8.04 (1H, s), 7.87-7.84 (4H, m), 7.58-7.54 (4H, m), 7.50-7.48 (2H, m), 7.31 (1H, s), 7.19 (1H, s), 3.77 (3H, s), 3.48 (3H, s), 3.17-3.03, 2.76-2.57, 2.54 (7H, m), 2.54 (3H, s); 13C NMR (CDCl3, 100 MHz) δ 160.0, 159.9, 149.2, 146.4, 146.1, 141.6, 134.8, 133.3, 133.2, 130.6, 130.4 (each qC), 129.8, 129.6, 129.5 (each CH), 129.5 (each qC), 129.3 (CH), 127.6 (qC), 122.1, 120.8, 120.7, 112.9 (each CH), 62.3 (CH), 61.1, 56.3 (each CH3), 52.7 (CH2), 43.8 (CH3), 33.4, 28.8 (each CH2); ESIMS m/z (rel. int. %): 616 (100, [M+H]+).
Based on the spectroscopic analysis, the 1H and 13C NMR spectroscopic data and ESIMS data of 1,10-dimethoxyaporphine are as follows:
1H NMR (CDCl3, 400 MHz) δ 7.90 (1H, d, J=2.6 Hz), 7.17 (1H, d, J=8.2 Hz), 7.04 (1H, d, J=8.4 Hz), 6.88 (1H, d, J=8.4 Hz), 6.78 (1H, dd, J=8.2, 2.6 Hz), 3.85 (3H, s), 3.83 (3H, s), 3.13-3.00, 2.70-2.55, 2.50-2.48 (7H, m), 2.54 (3H, s); 13C NMR (CDCl3, 100 MHz) δ 158.0, 154.9, 136.6, 133.0 (each qC), 128.6 (CH), 128.5 (qC), 128.1 (CH), 125.5, 121.9 (each qC), 114.7, 112.1, 110.8 (each CH), 63.2 (CH), 55.7, 55.3 (each CH3), 53.2 (CH2), 43.9 (CH3), 33.8, 28.5 (each CH2); ESIMS m/z (rel. int. %): 296 (100, [M+H]+).
In addition, the 1H NMR spectroscopic data and ESIMS data of 1,10-dihydroxyaporphine hydrobromide are as follows:
1H NMR (CD3OD, 400 MHz) δ 7.96 (1H, d, J=2.6 Hz), 7.18 (1H, d, J=8.2 Hz), 7.06 (1H, d, J=8.4 Hz), 6.96 (1H, d, J=8.4 Hz), 6.71 (1H, dd, J=8.2, 2.6 Hz), 4.25 (1H, br. d, J=10.6 Hz), 3.13 (3H, s); ESIMS m/z (rel. int. %): 268 (100, [M+H]+.
C2C12 skeletal myoblast cell line was purchased from the Food Industry Research and Development Institute (Hsinchu, Taiwan). The C2C12 cell line was a cell line obtained from culturing the leg skeletal muscle of adult C3H mice in a cell incubator under 95% O2, 5% CO2, and 37° C. The cells were cultured in a DMEM medium (Gibco/Invitrogen, Carlsbad, Calif.) containing 4.5 mg/mL glucose, 10% fetal bovine serum (FBS; Gibco/Invitrogen, Carlsbad, Calif.), and an antibiotic solution (with final concentrations of penicillin=100 IU/mL and streptomycin=100 μg/mL). When the C2C12 myoblast cells have proliferated to cover seven-tenths of the area in the petri dish, the fetal bovine serum was replaced by 2% horse serum (Gibco/Invitrogen, Carlsbad, Calif.) so as to induce the C2C12 myoblast cells to become the multi-nuclei myocytes. The C2C12 myoblast cells differentiated into myocytes in 4 days, and the culture medium of the cells was replaced with no-serum DMEM 24 hours before the experiments so as to reduce metabolism of the cells.
The C2C12 myocytes were treated respectively with 1 μM, 3 μM and 10 μM 1,10-dihydroxyaporphine hydrobromide for 5 and 15 minutes. Then the C2C12 myocytes were rinsed with PBS buffer solution, and RIPA buffer solution containing protease inhibitors (20 mM Tris-HCl (pH 7.4), 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40, and 100× protease inhibitor cocktail) was added into the cells. The cells were collected and centrifuged on ice. Then, the concentrations of the supernatant samples were adjusted to be the same.
The supernatant samples were put through vertical electrophoresis isolation with 8% SDS-PAGE, and the isolated proteins were transferred onto a PVDF blotting membrane. After blotting was completed, the PVDF blotting membrane was removed and blocked for 1 hour under room temperature with a blocking buffer of TBST (Tris-buffered saline with Tween-20) with 5% non-fat milk. Then, the PVDF blotting membrane was placed into a 5% BSA and TBST solution containing the primary monoclonal antibodies Phospho-AMPKα (Thr172) (Cell Signaling) (1:1000) and AMPKα (Thr172) (Cell Signaling) (1:1000), respectively, and the primary immunoblotting reaction was performed under 4° C. Then, the PVDF blotting membrane was rinsed 3 times with TBST, and a TBST solution containing the secondary antibody goat anti-rabbit IgG (Perkin Elmer) (1:10000) was added to perform the secondary reaction for one hour under room temperature. Finally, the membrane was rinsed 3 times with TBST before ECL (enhanced chemiluminescence) was added to present color.
Results
As shown in
Based on the results in the examples, one can see that aporphine alkaloid has an excellent effect in AMPK activation. In particularly, the 1,10-dihydroxyaporphine has an excellent effect in AMPK activation, wherein the 3 μM 1,10-dihydroxyaporphine hydrobromide for 5 min treatment has a pretty good effect in AMPK activation, and 10 μM 1,10-dihydroxyaporphine hydrobromide for 15 min treatment can provide the best effect in AMPK activation.
Number | Date | Country | Kind |
---|---|---|---|
103119114 | May 2014 | TW | national |